BioNet-Asia

BioNet-Asia is a Biotech company focused on the development and production of Nextgen vaccines in Asia. BioNet aims to provide a rapid access to life-saving vaccines to the neediest on all continents. BioNet is the only manufacturer of recombinant acellular Pertussis vaccines, produced by using a patented recombinant DNA technology. They contain a genetically-inactivated Pertussis Toxin (PTgen) which induces higher anti-PT immune response as demonstrated in several clinical trials. Two PTgen-containing vaccines are already available in Thailand: Pertagen®, a monovalent acellular Pertussis (aP) vaccine and Boostagen®, a Tetanus-diphtheria-acellular Pertussis (TdaP) combination vaccine which are used for booster immunization in adolescents and adults including pregnant women. BioNet has also been offering access to vaccines and technologies through global partnerships that have led to the supply of billions of doses of vaccines worldwide.